Integra Lifesciences Holdings Corp (NASDAQ:IART) major shareholder Richard E. Caruso sold 32,880 shares of the firm’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $53.68, for a total transaction of $1,764,998.40. The transaction was disclosed in a document filed with the SEC, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.
Shares of Integra Lifesciences Holdings Corp (IART) traded up $0.92 on Monday, hitting $55.77. 384,321 shares of the stock were exchanged, compared to its average volume of 510,734. The company has a current ratio of 2.36, a quick ratio of 1.51 and a debt-to-equity ratio of 1.85. The stock has a market capitalization of $4,305.41, a price-to-earnings ratio of 68.01, a PEG ratio of 1.69 and a beta of 0.65. Integra Lifesciences Holdings Corp has a twelve month low of $40.51 and a twelve month high of $56.42.
Integra Lifesciences (NASDAQ:IART) last announced its earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. The business had revenue of $368.60 million for the quarter, compared to analyst estimates of $362.64 million. Integra Lifesciences had a net margin of 5.45% and a return on equity of 16.94%. The company’s revenue for the quarter was up 44.2% compared to the same quarter last year. During the same period last year, the firm posted $0.52 earnings per share. analysts expect that Integra Lifesciences Holdings Corp will post 2.33 earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Integra Lifesciences by 38.3% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,806 shares of the life sciences company’s stock worth $182,000 after acquiring an additional 1,054 shares during the last quarter. Zions Bancorporation purchased a new position in shares of Integra Lifesciences during the third quarter worth approximately $205,000. Xact Kapitalforvaltning AB purchased a new position in shares of Integra Lifesciences during the fourth quarter worth approximately $311,000. Campbell Newman Asset Management Inc. grew its position in shares of Integra Lifesciences by 21.5% during the fourth quarter. Campbell Newman Asset Management Inc. now owns 6,964 shares of the life sciences company’s stock worth $333,000 after acquiring an additional 1,234 shares during the last quarter. Finally, Oppenheimer & Co. Inc. grew its position in shares of Integra Lifesciences by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 7,293 shares of the life sciences company’s stock worth $368,000 after acquiring an additional 1,466 shares during the last quarter. Institutional investors and hedge funds own 90.93% of the company’s stock.
About Integra Lifesciences
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.